Real World Study to Describe the Effectiveness and Safety of Teprotumumab among Thyroid Eye Disease Patients
Study Details
The main objective of this study is to assess the number of participants with proptosis response as of last intravenous infusion of teprotumumab.
Protocol Summary
Number of Participants with Proptosis Response as of the Last IV Infusion Teprotumumab
Timeframe: From baseline up to approximately 3 years
Demographics of Participants at Teprotumumab Initiation
Timeframe: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Body Mass Index at Index Date
Timeframe: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Smoking Status
Timeframe: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Disease Duration
Timeframe: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: TED Activity
Timeframe: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: TED Severity
Timeframe: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Eye symptoms
Timeframe: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Clinical Activity Score
Timeframe: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Computed Tomography (CT)/Magnetic Resonance Imaging (MRI) Measurements
Timeframe: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Quality of Life
Timeframe: From baseline up to approximately 3 years
Number of Participants with Relevant Medical History at Teprotumumab Initiation
Timeframe: From baseline up to approximately 3 years
Teprotumumab Use
Timeframe: From baseline up to approximately 3 years
Proptosis Measurements of Participants
Timeframe: From baseline up to approximately 3 years
Clinical Activity Scores (CAS) of Participants
Timeframe: From baseline up to approximately 3 years
Overall Response as of the Last Infusion Among Participants with Active TED
Timeframe: From baseline up to approximately 3 years
Diplopia Measurements for Participants
Timeframe: From baseline up to approximately 3 years
Quality of Life (QoL) as Reported by Participants
Timeframe: From baseline up to approximately 3 years
Incidence of Adverse Events (AEs)
Timeframe: From baseline up to approximately 3 years
Status of Specific AEs up to 6 Months After Last Infusion of Teprotumumab
Timeframe: From baseline up to approximately 3 years